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T h e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
corr e spondence
Isolated Tumor Cells in Breast Cancer
To the Editor: In their article, de Boer et al. 
(Aug. 13 issue)1 suggest that adjuvant systemic 
therapy may improve disease-free survival in breast 
cancer. However, the apparent treatment effect 
may also be due to imbalances in prognostic and 
predictive factors (such as hormone-receptor sta-
tus) that drive clinical decision making. The fail-
ure to distinguish between systemic chemother-
apy and hormonal therapy and the use of composite 
outcomes that are mostly unrelated to nodal in-
volvement further cloud the primary questions. 
Adjunctive hormonal therapy is currently recom-
mended in most patients with hormone-receptor–
positive tumors that are larger than 1 cm in di-
ameter on the basis of the characteristics of the 
primary tumor alone, leaving the question of any 
added benefit from chemotherapy unanswered.2,3 
This study raises important questions, but it should 
not be interpreted as a practice-changing study.
Gary H. Lyman, M.D., M.P.H. 
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To the Editor: In the absence of standardized 
therapy for occult nodal disease,1 de Boer et al. 
conclude, on the basis of a retrospective analysis 
involving 2707 patients with early breast cancer, 
that adjuvant chemotherapy improves disease-free 
survival in women with micrometastases or iso-
lated tumor cells detected in a sentinel-lymph-node-
biopsy specimen.
The lack of randomization and wide heteroge-
neity limit the power of this study. Among pa-
tients with micrometastases at baseline, axillary 
lymph-node dissection alone and axillary lymph-
node dissection, axillary irradiation, or both were 
more often performed in the adjuvant-therapy 
group than in the no-adjuvant-therapy group 
(75.4% vs. 54.6% and 84.6% vs. 61.1%, respec-
tively; P<0.001 for both comparisons). This more 
aggressive locoregional treatment in the adjuvant-
therapy group makes the comparison unreliable. 
Additional differences in tumor grade and estro-
gen-receptor status between the previously men-
tioned groups and the lack of consideration of the 
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human epidermal growth factor receptor type 2 
(HER2) status and trastuzumab treatment further 
limit the comparison of effectiveness.
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To the Editor: Although the study reported on 
by de Boer et al. accounted for unequal distribu-
tions of most established prognostic factors in 
breast cancer, residual confounding may still have 
influenced the results. In particular, the lack of 
regard for molecular subtypes may have played a 
role. In luminal (i.e., estrogen-receptor–positive, 
HER2-negative) breast cancer, most events occur 
after the study end point of 5 years. The basal and 
HER2-positive subtypes will therefore drive the 
presented data. Data on HER2 status, however, 
are not provided. Moreover, trastuzumab was ad-
ministered within the context of a clinical trial in 
some, but not all, of the Dutch hospitals during 
the inclusion period of the study. Small imbalances 
in the distribution of molecular subtypes and of 
anti-HER2–targeted therapy may thus have had a 
large effect on the outcome. The study would ben-
efit from a stratified analysis according to the mo-
lecular subtype and with adjustment for the hos-
pital. Also, modern molecular tools such as the 
70-gene signature and the 21-gene recurrence score 
outweigh the impact of traditional prognostic fac-
tors and may be of particular value in patients with 
micrometastases or isolated tumor cells.
Gabe S. Sonke, M.D., Ph.D. 
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The Authors Reply: We reported that isolated 
tumor cells and micrometastases in lymph nodes 
in women with early-stage breast cancer were as-
sociated with an absolute reduction in the 5-year 
rate of disease-free survival of nearly 10 percent-
age points.1 In patients with such findings who 
had received adjuvant systemic therapy, the dis-
ease-free survival was improved as compared with 
patients who did not receive adjuvant therapy.
Lyman and Peppercorn advise caution because 
of possible imbalances in factors such as hormone-
receptor status. In a Cox proportional-hazards 
model including hormone-receptor status, we 
found a hazard ratio for events (including distant 
metastases) of 1.51 (95% confidence interval [CI], 
1.20 to 1.90) if the nodes were abnormal. We 
found that in patients with small metastases, com-
bined chemotherapy and endocrine treatment was 
associated with an adjusted hazard ratio for events 
of 0.34 (95% CI, 0.21 to 0.55), whereas the hazard 
ratio associated with endocrine therapy alone was 
0.60 (95% CI, 0.46 to 0.80).1 In the treatment-relat-
ed analyses, we did not consider hormone-recep-
tor status, since it partially determined the treat-
ment allocation. The benefit from combination 
treatment is consistent with published data.1
Roukos questions whether heterogeneity in lo-
coregional treatment or tumor grade explains the 
results. As reported, after adjustment for tumor 
grade and axillary treatment, there remained a 
reduced risk of events among patients who were 
treated with systemic therapy (hazard ratio, 0.57; 
95% CI, 0.45 to 0.73). From 1997 through 2005, 
neither HER2 testing nor the routine use of ad-
juvant trastuzumab had been fully implemented 
(except in some patients in trials). If patients in 
the adjuvant-therapy cohort had received trastu-
zumab, the influence of systemic therapy would 
have been even greater.
Sonke and Linn hypothesize that basal and 
HER2-positive subtypes drive the data, because in 
luminal breast cancer most events occur more 
than 5 years after the diagnosis. There is little 
evidence to support this assumption, since less 
than 8% of the patients in our study had a 
grade 3, or hormone-receptor–negative, tumor. 
Moreover, the decrease in disease-related events 
due to systemic therapy was largely the result of 
endocrine therapy. It is not at all clear yet wheth-
er gene signatures “outweigh the impact of tra-
ditional prognostic factors.” A study that reana-
lyzed the data from the original article by van ’t 
Veer et al.2 showed that a multivariate classifi-
cation based on tumor grade, tumor size, and 
lymph-node status had an association with out-
come that was as good as the 70-gene signature.3 
Because of the magnitude of the effect of small 
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metastases on disease-free survival, we conclude 
that small metastases can no longer be ignored.
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Age-Related Memory Decline and the APOE ε4 Effect
To the Editor: Cognitive decline is a complex 
multifactorial process, and so it is important to 
exclude as many potentially confounding variables 
as possible when assessing the influence of a sin-
gle factor. In their longitudinal study, Caselli and 
colleagues (July 16 issue)1 apparently did not take 
into account some such variables, including alco-
hol consumption, mentally stimulating activities, 
and smoking.2-4 In addition, physical inactivity is 
reported to be a risk factor for cognitive decline, 
especially among persons carrying the apolipo-
protein E (APOE) ε4 allele.5
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To the Editor: Caselli et al. note that accelerat-
ed memory decline among persons with the APOE 
ε4 allele may be caused by subclinical Alzheimer’s 
disease. Subclinical and clinical vascular cogni-
tive impairment are also prevalent among older 
adults. There is some evidence that cerebrovascu-
lar impairment and cognitive impairment have 
common risk factors.1 Indeed, diabetes, hyperten-
sion, and the APOE ε4 genotype independently 
contribute to cognitive decline in late middle age 
and beyond.2 Caselli et al. investigated the tempo-
ral effect of APOE ε4 on cognition, but they do not 
provide information on the vascular risk factors of 
the subjects, and so the possibility that these risk 
factors could have had an effect on the reported 
memory decline cannot be ruled out.
Lei Ma, M.D. 
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The Authors Reply: We, too, are concerned about 
the multiple factors that might influence cogni-
tive trajectories. There is little question regarding 
the potentially adverse influences of substance 
abuse and stroke, and so persons who reported a 
history of substance abuse or stroke were exclud-
ed from the study. Furthermore, anyone in whom 
mild cognitive impairment or dementia developed 
at any time, for any reason, was excluded. 
In our cohort, there was no difference between 
APOE ε4 carriers and noncarriers with respect to 
the prevalence of hypertension (24.7% vs. 27.7%, 
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